Insulin resistance and the endothelium

This publication has 92 references indexed in Scilit:

• The central role of fat and effect of peroxisome proliferator-activated receptor–γ on progression of insulin resistance and cardiovascular disease
  The American Journal of Cardiology, 2003
• Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects
  British Journal of Clinical Pharmacology, 2002
• Effects of Antihypertensive Drugs on Endothelial Dysfunction
  Drugs, 2002
• HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species
  Hypertension, 2001
• Tissue Angiotensin and Pathobiology of Vascular Disease
  Hypertension, 2001
• Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells
  Life Sciences, 2000
• Endothelial Function in Hypertension
  Hypertension, 1999
• Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
  Journal of Clinical Investigation, 1998
• Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
  Journal of Clinical Investigation, 1995
• Nitric oxide release accounts for insulin's vascular effects in humans.
  Journal of Clinical Investigation, 1994